Drug Trial Radar · NCT04223791
Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)
Last checked: Nov 19, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
643
Actual
Start
Feb 18, 2020
Primary completion
Aug 26, 2021
Study completion Feb 27, 2025
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Jan 10, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety and efficacy of a switch to Doravirine/Islatravir (DOR/ISL) (MK-8591A) (a fixed dose combination of doravirine 100 mg and islatravir 0.75 mg) in participants living with human immunodeficiency virus-1 (HIV-1) virologically suppressed on a regimen of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF). The primary hypothesis is that a switch to DOR/ISL (MK-8591A) will be non-inferior to continued treatment with BIC/FTC/TAF as assessed by the proportion of participants with HIV-1 ribonucleic acid (RNA) ≥50 copies/mL at Week 48. Participants who benefit from their assigned intervention (as determined by investigator) will be able to continue treatment through a 24-week study extension.
Conditions
- HIV Infection
Interventions
DOR/ISLDrug
100 mg DOR/ 0.75 ISL FDC single tablet taken orally once daily
BIC/FTC/TAFDrug
50 mg BIC, 200 mg FTC, and 25 mg TAF combined in a single tablet, taken orally once daily
Placebo to BIC/FTC/TAFDrug
Placebo to BIC/FTC/TAF in a single tablet taken orally, once daily
Placebo to FDC DOR/ISLDrug
Placebo to FDC DOR/ISL in a single tablet taken orally, once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Human Immunodeficiency Virus 1 Ribonucleic Acid (HIV-1 RNA) ≥50 Copies/mL at Week 48Time frame: Week 48
- Percentage of Participants With One or More Adverse Events (AEs) up to Week 48Time frame: Up to 48 weeks
- Percentage of Participants Who Discontinued Study Intervention Due to an AE up to Week 48Time frame: Up to 48 weeks
Locations
89 sites in 11 countries. Site status is shown where the registry gives one.
Pueblo Family Physicians ( Site 2717)
Phoenix, Arizona
Pacific Oaks Medical Group ( Site 2765)
Beverly Hills, California
Men's Health Foundation ( Site 2749)
Los Angeles, California
Kaiser Permanente Los Angeles Medical Center ( Site 2775)
Los Angeles, California
Eisenhower Medical Center ( Site 2744)
Palm Springs, California
University of California, Davis, Division of ID Research ( Site 2702)
Sacramento, California
Zuckerberg San Francisco General Hospital UCSF ( Site 2743)
San Francisco, California
Whitman-Walker Clinic ( Site 2728)
Washington D.C., District of Columbia
TheraFirst Medical Center ( Site 2742)
Fort Lauderdale, Florida
Midway Immunology and Research ( Site 2759)
Ft. Pierce, Florida
The Kinder Medical Group ( Site 2739)
Miami, Florida
AHF South Beach ( Site 2780)
Miami Beach, Florida
Orlando Immunology Center ( Site 2734)
Orlando, Florida
Triple O Research Institute, P.A. ( Site 2755)
West Palm Beach, Florida
Augusta University ( Site 2752)
Augusta, Georgia
Infectious Disease Specialists Of Atlanta PC ( Site 2719)
Decatur, Georgia
Mercer University ( Site 2738)
Macon, Georgia
Chatham County Health Department ( Site 2731)
Savannah, Georgia
Hennepin County Medical Center ( Site 2733)
Minneapolis, Minnesota
Kansas City CARE Clinic ( Site 2718)
Kansas City, Missouri
ID Care ( Site 2751)
Hillsborough, New Jersey
Icahn School of Medicine at Mount Sinai ( Site 2700)
New York, New York
Montefiore Einstein Center ( Site 2730)
The Bronx, New York
North Texas ID Consultants, PA ( Site 2707)
Dallas, Texas
The Crofoot Research Center, Inc. ( Site 2715)
Houston, Texas
DCOL Center for Clinical Research ( Site 2769)
Longview, Texas
Dr. Peter Shalit, MD ( Site 2770)
Seattle, Washington
Multicare Health System ( Site 2713)
Spokane, Washington
St Vincent's Hospital ( Site 3807)
Darlinghurst, New South Wales, Australia
Taylor Square Private Clinic ( Site 3804)
Darlinghurst, New South Wales, Australia
Holdsworth House Medical Practice ( Site 3800)
Sydney, New South Wales, Australia
Holdsworth House Medical Practice - Brisbane ( Site 3810)
Brisbane, Queensland, Australia
Royal Brisbane and Womens Hospital- Infectious Diseases Unit ( Site 3812)
Herston, Queensland, Australia
The Alfred Hospital ( Site 3802)
Melbourne, Victoria, Australia
Prahran Market Clinic (PMC) ( Site 3806)
Melbourne, Victoria, Australia
Medical University Vienna ( Site 3402)
Vienna, State of Vienna, Austria
Sozialmedizinisches Zentrum Sued - Kaiser-Franz-Josef-Spital ( Site 3400)
Vienna, State of Vienna, Austria
Social Medical Center - Otto Wagner Hospital ( Site 3404)
Vienna, State of Vienna, Austria
LKH Graz West ( Site 3401)
Graz, Styria, Austria
Vancouver ID Research and Care Centre Society ( Site 2800)
Vancouver, British Columbia, Canada
Showing 40 of 89 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.